Biofrontera Inc. (NASDAQ: BFRI) announced results from its Phase 2b clinical trial evaluating Ameluz photodynamic therapy for moderate to severe ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE